Roche Forecast, price target & analysts
Roche Target price 2025 - Analyst rating & recommendation
Roche Classifications & Recommendation:
Roche Price Target
| Target Price | CHF297.84 |
| Price | CHF262.60 |
| Potential | 13.42% |
| Number of Estimates | 22 |
| 22 Analysts have issued a price target Roche 2026 . The average Roche target price is CHF297.84. This is 13.42% higher than the current stock price. The highest price target is CHF459.90 75.13% , the lowest is CHF237.35 9.62% . | |
| A rating was issued by 26 analysts: 13 Analysts recommend Roche to buy, 9 to hold and 4 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Roche stock has an average upside potential 2026 of 13.42% . Most analysts recommend the Roche stock at Purchase. |
Sales and Margin forecast 2025, 2026 to 2032
22 Analysts have issued a sales forecast Roche 2025 . The average Roche sales estimate is CHF63.4b . This is 4.84% higher than the revenue of the last 12 months(TTM). The highest sales forecast is CHF69.8b 15.32% , the lowest is CHF59.9b 1.03% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | CHF60.5b | 3.03% |
|---|---|---|
| 2025 | CHF63.4b | 4.84% |
| 2026 | CHF65.4b | 3.19% |
| 2027 | CHF67.2b | 2.72% |
| 2028 | CHF70.0b | 4.16% |
| 2029 | CHF74.3b | 6.07% |
| 2030 | CHF77.6b | 4.46% |
| 2031 | CHF83.0b | 6.94% |
| 2032 | CHF85.0b | 2.49% |
21 Analysts have issued an Roche EBITDA forecast 2025. The average Roche EBITDA estimate is CHF25.3b . This is 23.81% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is CHF28.6b 39.97% , the lowest is CHF21.7b 6.02% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | CHF20.4b | 8.34% |
|---|---|---|
| 2025 | CHF25.3b | 23.81% |
| 2026 | CHF26.5b | 4.67% |
| 2027 | CHF27.3b | 3.19% |
| 2028 | CHF29.5b | 8.11% |
| 2029 | CHF32.6b | 10.41% |
| 2030 | CHF34.9b | 6.96% |
| 2031 | CHF37.4b | 7.08% |
| 2032 | CHF39.0b | 4.46% |
EBITDA Margin
| 2024 | 33.78% | 5.15% |
|---|---|---|
| 2025 | 39.90% | 18.10% |
| 2026 | 40.47% | 1.43% |
| 2027 | 40.66% | 0.47% |
| 2028 | 42.20% | 3.79% |
| 2029 | 43.93% | 4.10% |
| 2030 | 44.98% | 2.39% |
| 2031 | 45.04% | 0.13% |
| 2032 | 45.91% | 1.93% |
22 Roche Analysts have issued a net profit forecast 2025. The average Roche net profit estimate is CHF16.0b . This is 93.75% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is CHF17.8b 115.54% , the lowest is CHF14.6b 75.92% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | CHF8.3b | 28.01% |
|---|---|---|
| 2025 | CHF16.0b | 93.75% |
| 2026 | CHF16.8b | 4.70% |
| 2027 | CHF17.5b | 4.46% |
| 2028 | CHF19.0b | 8.24% |
| 2029 | CHF20.3b | 7.09% |
| 2030 | CHF21.6b | 6.24% |
| 2031 | CHF23.2b | 7.49% |
| 2032 | CHF23.9b | 2.79% |
Net Margin
| 2024 | 13.68% | 30.13% |
|---|---|---|
| 2025 | 25.29% | 84.84% |
| 2026 | 25.66% | 1.46% |
| 2027 | 26.09% | 1.68% |
| 2028 | 27.11% | 3.91% |
| 2029 | 27.38% | 1.00% |
| 2030 | 27.84% | 1.68% |
| 2031 | 27.99% | 0.54% |
| 2032 | 28.07% | 0.29% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
22 Analysts have issued a Roche forecast for earnings per share. The average Roche EPS is CHF20.16 . This is 95.35% higher than earnings per share in the financial year 2024. The highest EPS forecast is CHF22.43 117.34% , the lowest is CHF18.31 77.42% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | CHF10.32 | 27.83% |
|---|---|---|
| 2025 | CHF20.16 | 95.35% |
| 2026 | CHF21.11 | 4.71% |
| 2027 | CHF22.05 | 4.45% |
| 2028 | CHF23.87 | 8.25% |
| 2029 | CHF25.56 | 7.08% |
| 2030 | CHF27.16 | 6.26% |
| 2031 | CHF29.19 | 7.47% |
| 2032 | CHF30.00 | 2.77% |
P/E ratio
| Current | 25.45 | 18.96% |
|---|---|---|
| 2025 | 13.02 | 48.83% |
| 2026 | 12.44 | 4.45% |
| 2027 | 11.91 | 4.26% |
| 2028 | 11.00 | 7.64% |
| 2029 | 10.27 | 6.64% |
| 2030 | 9.67 | 5.84% |
| 2031 | 9.00 | 6.93% |
| 2032 | 8.75 | 2.78% |
Based on analysts' sales estimates for 2025, the Roche stock is valued at an EV/Sales of 3.65 and an P/S ratio of 3.37 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 3.82 | 12.59% |
|---|---|---|
| 2025 | 3.65 | 4.55% |
| 2026 | 3.53 | 3.09% |
| 2027 | 3.44 | 2.65% |
| 2028 | 3.30 | 4.00% |
| 2029 | 3.11 | 5.72% |
| 2030 | 2.98 | 4.27% |
| 2031 | 2.79 | 6.49% |
| 2032 | 2.72 | 2.43% |
P/S ratio
| Current | 3.54 | 10.16% |
|---|---|---|
| 2025 | 3.37 | 4.61% |
| 2026 | 3.27 | 3.09% |
| 2027 | 3.18 | 2.64% |
| 2028 | 3.05 | 4.00% |
| 2029 | 2.88 | 5.72% |
| 2030 | 2.76 | 4.26% |
| 2031 | 2.58 | 6.49% |
| 2032 | 2.52 | 2.43% |
Current Roche Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BERENBERG |
Hold
➜
Hold
|
Unchanged | Jul 17 2025 |
| TD COWEN |
Hold
➜
Hold
|
Unchanged | Jul 13 2025 |
| ROTHSCHILD & CO REDBURN |
Buy
➜
Buy
|
Unchanged | Jul 01 2025 |
| JEFFERIES |
Hold
➜
Hold
|
Unchanged | Jun 04 2025 |
| HSBC |
Buy
➜
Hold
|
Downgrade | May 25 2025 |
| DZ BANK |
Buy
➜
Buy
|
Unchanged | Apr 27 2025 |
| BERENBERG |
Hold
➜
Hold
|
Unchanged | Apr 07 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
BERENBERG:
Hold
➜
Hold
|
Jul 17 2025 |
|
Unchanged
TD COWEN:
Hold
➜
Hold
|
Jul 13 2025 |
|
Unchanged
ROTHSCHILD & CO REDBURN:
Buy
➜
Buy
|
Jul 01 2025 |
|
Unchanged
JEFFERIES:
Hold
➜
Hold
|
Jun 04 2025 |
|
Downgrade
HSBC:
Buy
➜
Hold
|
May 25 2025 |
|
Unchanged
DZ BANK:
Buy
➜
Buy
|
Apr 27 2025 |
|
Unchanged
BERENBERG:
Hold
➜
Hold
|
Apr 07 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
